Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly - 21/12/17
, Allison K. Cabalka, MD a, Andreas Eicken, MD, PhD b, Jamil A. Aboulhosn, MD c, John D.R. Thomson, MD d, Brian Whisenant, MD e, Martin L. Bocks, MD f, Stephan Schubert, MD g, Thomas K. Jones, MD h, Jeremy D. Asnes, MD i, Thomas E. Fagan, MD j, Jeffery Meadows, MD k, Mark Hoyer, MD l, Mary H. Martin, MD m, Frank F. Ing, MD n, Daniel R. Turner, MD o, Azeem Latib, MBBCh p, Aphrodite Tzifa, MD q, Stephan Windecker, MD r, Bryan H. Goldstein, MD s, Jeffrey W. Delaney, MD t, James A. Kuo, MD u, Susan Foerster, MD v, Matthew Gillespie, MD w, Gianfranco Butera, MD, PhD x, Shabana Shahanavaz, MD y, Eric Horlick, MD z, Younes Boudjemline, MD, PhD aa, Daniel Dvir, MD bb, Doff B. McElhinney, MD ccfor the
VIVID Registry
Abstract |
We sought to describe the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). Cases were identified from a voluntary, multicenter, international registry of 29 institutions that perform TVIV. Demographic, clinical, procedural, and follow-up data were analyzed. Eighty-one patients with EA underwent TVIV from 2008 to 2016. Thirty-four patients (42%) were New York Heart Association (NYHA) class 3/4 at time of TVIV. The most common indication for TVIV was the presence of moderate or severe tricuspid regurgitation (40%). Most patients received a Melody valve (64%). TVIV was ultimately successful in all patients, and there was no procedural mortality. Four patients (5%) developed acute valve thrombosis, 4 patients (5%) developed endocarditis, and 9 patients (11%) developed valve dysfunction not related to thrombosis or endocarditis. Eight patients (10%) underwent reintervention (2 transcatheter, 6 surgical) due to thrombosis (3), endocarditis (2), other valve dysfunction (2), and patient-prosthesis mismatch without valve dysfunction (1). Among 69 patients who were alive without reintervention at latest follow-up, 96% of those with NYHA status reported were class 1/2, a significant improvement from baseline (62% NYHA class 1/2, p <0.001). In conclusion, transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis.
Le texte complet de cet article est disponible en PDF.Plan
| See page 267 for disclosure information. |
|
| Funding sources: The authors report no external funding related to the publication of this manuscript. |
Vol 121 - N° 2
P. 262-268 - janvier 2018 Retour au numéro
Article précédent
- Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial)
- Peter J. Leary, Richard A. Kronmal, David A. Bluemke, Peter M. Buttrick, Kenneth L. Jones, David P. Kao, Steven M. Kawut, Eric V. Krieger, Joao A. Lima, Wayne Minobe, David D. Ralph, Ryan J. Tedford, Noel S. Weiss, Michael R. Bristow
- Lewis Grizzard and his Bicuspid Aortic Valve
- Michael C. Trotter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?